Option Therapeutics Statistics
Total Valuation
| Market Cap | n/a |
| Enterprise Value | n/a |
Important Dates
The last earnings date was Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 10.13M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +49.39% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 5.36% |
| Owned by Institutions (%) | 39.68% |
| Float | 6.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 1.14 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -106.74% and return on invested capital (ROIC) is -106.74%.
| Return on Equity (ROE) | -106.74% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -106.74% |
| Return on Capital Employed (ROCE) | 26.32% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.82 |
| Inventory Turnover | 0.72 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Dividends & Yields
OPTN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -49.39% |
| Shareholder Yield | -49.39% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OPTN is $9.00, which is -6.25% lower than the current price. The consensus rating is "Hold".
| Price Target | $9.00 |
| Price Target Difference | -6.25% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 23.94% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 31, 2024. It was a reverse split with a ratio of 0.0666667:1.
| Last Split Date | Dec 31, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0666667:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |